81 FR 66282 - Statement of Organization, Functions, and Delegations of Authority
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 81, Issue 187 (September 27, 2016)
Centers for Disease Control and Prevention
Federal Register Volume 81, Issue 187 (September 27, 2016)
| Page Range | 66282-66284 | |
| FR Document | 2016-23213 |
[Federal Register Volume 81, Number 187 (Tuesday, September 27, 2016)] [Notices] [Pages 66282-66284] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-23213] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Statement of Organization, Functions, and Delegations of Authority Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 81 FR 54091-54094, dated August 15, 2016) is amended to reflect the reorganization of the Division of Healthcare Quality and Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Office of Infectious Diseases, Centers for Disease Control and Prevention. Section C-B, Organization and Functions, is hereby amended as follows: Delete and replace the title and the mission and function statements for the Division of Healthcare Quality and Promotion (CVLD) and insert the following: Division of Healthcare Quality Promotion (CVLD). Protects patients and healthcare personnel, and promotes safety, quality, and value in both national and international healthcare delivery systems. In carrying out its mission, Division of Healthcare Quality Promotion (DHQP): (1) Measures, validates, interprets, and responds to data relevant to healthcare-associated infections (HAI); antimicrobial use and resistant infections, sepsis, adverse drug events, blood, organ and tissue safety, immunization safety, and other related adverse events or medical errors in healthcare affecting patients and healthcare personnel; (2) investigates and responds to emerging infections, antimicrobial resistance, and related adverse events among patients and healthcare personnel; (3) develops and maintains the National Healthcare Safety Network (NHSN), a tool for monitoring healthcare- associated infections, antimicrobial use and resistance, measuring healthcare outcomes and processes, and monitoring healthcare worker vaccination and selected health measures in healthcare facilities; (4) assesses local, regional, national scope and burden of infections caused by resistant-bacteria in the U.S. through surveillance and special studies, review of national healthcare data sets, and laboratory surveillance programs; (5) conducts epidemiologic, and basic and applied laboratory research to identify new strategies to monitor and prevent infections/antimicrobial resistance, and related adverse events or medical errors, especially those associated with medical or surgical procedures, indwelling medical devices, contaminated products, dialysis, healthcare environment, and water; (6) collaborates with academic and public health partners to design, develop, and evaluate new approaches to monitoring infections and the efficacy of interventions for preventing infections, improving antibiotic use, and reducing antimicrobial resistance, and related adverse events or medical errors; (7) develops and disseminates evidence-based guidelines and recommendations to prevent and control HAI, antimicrobial resistance (AR), and related adverse events or medical errors; (8) collaborates with Federal, state, and local public health and private partners to promote nationwide implementation of CDC guidelines and other evidence-based interventions to prevent HAI, antimicrobial resistance, and related adverse events or medical errors among patients and healthcare personnel; (9) evaluates the impact of evidence-based recommendations and interventions across the spectrum of healthcare delivery sites; (10) serves as the Designated Federal Official for the Healthcare Infection Control Practices Advisory Committee (HICPAC); (11) serves as the National Reference Laboratory for the identification and antimicrobial susceptibility testing of staphylococci, anaerobic bacteria, non-tuberculous mycobacterial, and those gram-negative bacilli causing healthcare-associated infections; (12) serves as the technical reference laboratory for detection and characterization of other pathogens related to healthcare, and for characterizing the contribution of the healthcare environment to HAI and antimicrobial resistant infections; (13) serves as a global resource for HAI, antimicrobial resistance, and device-associated HAI; (14) coordinates guidance and research related to infection control across CDC and with national and international partners; (15) monitors vaccine safety and conducts research to evaluate the safety of available and new vaccines; (16) trains EIS Officers and other trainees; (17) coordinates antimicrobial resistance activities at CDC; (18) works in a national leadership capacity with public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, and applied research; (19) coordinates blood, organ, and other tissue safety at CDC; and (20) provides expertise and assistance to HHS, other Federal agencies, and global partners on efforts and activities related to safe healthcare. Office of the Director (CVLD1). (1) Manages, directs, and coordinates the activities of DHQP; (2) provides leadership and guidance on policy impacting patient and healthcare safety; (3) leads targeted patient safety communication campaigns coordinated with release of CDC surveillance data, infection control guidelines, research publications, and prevention tools; (4) fosters strategic partnerships with clinical professional organizations to advance implementation of CDC's recommendations and best clinical practices; (5) leads communication/media outreach to include social media platforms and CDC's patient and healthcare safety Web sites; (6) works with Federal agencies, international organizations, and other partners on activities related to safe healthcare; (7) coordinates state and local activities to monitor and prevent HAI and antimicrobial resistance; (8) coordinates activities related to infection control in healthcare and related settings including, guideline development and maintenance, interim guidance development, training, consultation, and international activities across DHQP, CDC, and with national and international partners; (9) coordinates DHQP activities and collaborates with the CDC EOC for emergency response to emerging infections in healthcare; (10) coordinates DHQP activities and collaborates with other CIOs and Federal agencies to prepare healthcare to respond to emerging threats; (11) oversees the quality of DHQP research activities and identifies research gaps; (12) leads CDC's activities on blood, organ, and other tissue safety; (13) represents CDC on the Advisory Committee on Blood Safety and Availability, and the Advisory Committee on Organ Transplantation; (14) works with other Federal agencies, state governments, and other public and private organizations to enhance blood, organ, and other tissue safety through coordination of investigation, prevention, response, surveillance, [[Page 66283]] applied research, health communication, and public policy; (15) provides leadership and guidance for program planning and development, program management, and operations; (16) provides DHQP-wide administrative and program services, and coordinates or ensures coordination with the appropriate CIOs and CDC staff offices on administrative and program matters including, budget formulation and execution, and human resource management; (17) oversees the coordination of Federal and state programs and new initiatives to prevent HAI and antimicrobial resistance; (18) interprets general program and administrative policy directives for implications on management and execution of DHQP's programs; (19) serves as lead, primary contact, and liaison with relevant CDC Staff Offices on all matters pertaining to DHQP's procurement needs and activities; (20) provides management and coordination for DHQP-occupied space and facilities including laboratory space and facilities; (21) provides oversight and management of the distribution, accountability, and maintenance of CDC property and equipment including laboratory property and equipment; (22) provides program and administrative support for HICPAC; and (23) advises the Director, NCEZID, on science, policy and communication matters concerning DHQP activities. Antimicrobial Resistance Coordination and Strategy Unit (CVLD13). (1) Oversees the coordination of AR activities at CDC to meet national goals; (2) represents CDC in interagency activities on AR including the President's Advisory Committee for Combatting Antibiotic Resistant Bacteria (PAC-CARB); (3) coordinates with other agencies, state governments, medical societies, and other public and private organizations to enhance AR prevention and control, surveillance and response, and applied research; (4) represents CDC at the Transatlantic Task Force on Antimicrobial Resistance; (5) oversees CDC AR budget to implement AR activities as part of the Federal Action Plan to Combat Antibiotic Resistant Bacteria; (6) coordinates policies and communications associated to CDC-wide programs related to AR; (7) ensures coordination with appropriate CIOs and CDC staff offices on AR program matters, including budget formulation and execution; (8) provides updates and reports about CDC AR activities and progress to the CDC Director, HHS, and the White House; and (9) oversees coordination of CDC collaborations and new Federal initiatives to detect, respond and prevent antimicrobial resistance. International Infection Control Activity (CVLD14). (1) Leads, in collaboration with the appropriate CIO and CDC components, global health activities related to the prevention of HAI, antimicrobial resistance, and related adverse events or medical errors; (2) coordinates international efforts to establish and improve infection prevention and control policies, programs, and coordination; (3) assists countries to improve infection prevention and control capacity toward prevention and control of HAI disease outbreaks and device- associated HAIs; (4) collaborates with ministries of health, CDC country offices, and implementing partners, to develop country-specific national policies and action plans to reduce the global burden of antimicrobial resistance associated with healthcare delivery; and (5) provides technical assistance to partners in building antimicrobial resistance laboratory capacity and surveillance systems. Clinical and Environmental Microbiology Branch (CVLDB). (1) Leads national laboratory characterization of HAI-related threats in partnership with state and regional laboratories; (2) provides comprehensive laboratory support and expertise for investigations of recognized and emerging pathogens in healthcare settings, such as methicillin-resistant S. aureus, carbapenem-resistant Enterobacteriaceae (CRE), and Clostridium difficile; (3) provides laboratory response to outbreaks and emerging threats associated with infections/antimicrobial resistance and related adverse events throughout the healthcare delivery system; (4) develops methods to assess contamination of environmental surfaces; (5) investigates novel and emerging mechanisms of antimicrobial resistance among targeted pathogens found in healthcare settings; (6) conducts research in collaboration with partners to develop new, accurate methods of detecting antimicrobial resistance in bacteria and to improve reporting of antimicrobial susceptibility test results to physicians to improve antimicrobial use; (7) conducts laboratory research to identify new strategies to prevent infections/antimicrobial resistance, related adverse events, and medical errors, especially those associated with invasive medical devices, contaminated products, dialysis, and water; (8) maintains capacity to evaluate commercial microbial identification, antimicrobial susceptibility testing systems and products, and facilitates their improvement to provide accurate patient test results; (9) investigates the role of biofilms, particularly those detected in indwelling medical devices and medical water systems, in medicine and public health, and identifies novel methods to eliminate colonization and biofilm formation on foreign bodies; (10) investigates the role of microbiome in the prevention of infections and antimicrobial resistance; (11) investigates the role of the water distribution systems in healthcare facilities in order to understand and prevent transmission of healthcare-associated infections due to water; and (12) provides expertise, research opportunities, training, and laboratory support for investigations of infections and related adverse events to other CDC CIOs and to our partners in areas related to quality clinical microbiology laboratory practices, investigation of emerging pathogens, and environmental microbiology. Prevention and Response Branch (CVLDC). Across the healthcare continuum, including acute, long-term, ambulatory, and chronic care settings: (1) Develops, promotes, and monitors implementation of evidence-based recommendations, standards, policies, strategies and related educational materials to prevent and control HAI, and related adverse events, and healthcare personnel safety events associated with antibiotic resistance, device, and procedure associated infections, poor adherence to quality standards and safety, and emerging infectious diseases; (2) develops, promotes, and monitors implementation of and adherence to evidence-based recommendations, standards and related educational materials, policies and strategies to increase adherence to appropriate antimicrobial use and stewardship; (3) uses data from the National Healthcare Safety Network (NHSN) and other sources to target and improve the prevention and control healthcare-associated infections and antimicrobial resistance in the U.S. in specific regions, settings and institutions; (4) supports local, state, and national efforts to prevent HAI, antimicrobial resistance, and related adverse events by providing leadership and consultative services, including monitoring adherence to CDC-recommended practices; (5) provide leadership and epidemiologic support for the investigation, monitoring, and control of both recognized and emerging healthcare pathogens, including antimicrobial resistant bacteria; (6) leads response and control of outbreaks and emerging threats involving HAI and [[Page 66284]] related adverse events, contaminated medical products and devices, and adverse drug events; (7) communicates the results of response activities with Federal and state agencies, healthcare providers, and the public, with recommendations to prevent similar adverse events in the future; and (8) provides leadership and expert consultation, guidance, and technical support to and collaborates with other CDC CIOs and divisions, other HHS Operating Divisions, and extramural domestic partners, on the epidemiology, prevention, and control of HAI, AR, and related adverse events; (9) implements state activities to prevent HAI and AR across healthcare; and (10) leads CDC activities to promote antimicrobial stewardship in all healthcare settings. Surveillance Branch (CVLDD). (1) Monitors and evaluates on the national level the extent, distribution, and impact of HAI, antimicrobial use and resistance, adverse drug events, healthcare worker safety events, and adherence to clinical processes and intervention programs designed to prevent or control adverse exposures or outcomes in healthcare; (2) provides services, including leadership, consultation, and analysis support, for statistical methods and analysis to investigators in the branch, division, and other organizations responsible for surveillance, research studies, and prevention and control of HAI and other healthcare-associated adverse events; (3) works with the Centers for Medicare and Medicaid Services and other partners to develop new metrics and support maintenance of National Quality Forum-approved metrics; (4) collaborates with public and private sector partners to further standardize, integrate, and streamline systems by which healthcare organizations collect, manage, analyze, report, and respond to data on clinical guideline adherence, HAI, including transmission of multi-drug resistant organisms, and other HAI; (5) coordinates, further develops, enables wider use, and maintains NHSN to obtain scientifically valid clinical performance indices that promote healthcare quality and value at the facility, state, and national levels; (6) develops and implements new NHSN modules and provides enrollment and user support for NHSN; (7) improves surveillance systems by utilizing new technology; (8) generates and provides NHSN surveillance reports and analyses, which include collaborative analytic projects with partners; and (9) leads CDC's national adverse drug events surveillance activities and seeks to translate population-based surveillance data into evidence-based policies and targeted, innovative and collaborative interventions. Immunization Safety Office (CVLDE). Assesses the safety of new and currently available vaccines received by children, adolescents and adults using a variety of strategies: (1) Conducts ongoing surveillance for the timely detection of possible adverse events following immunization (AEFI) in collaboration with the Food and Drug Administration (FDA), through coordination and management of the Vaccine Adverse Event Reporting System, the national reporting system that acts as an early-warning system to detect health conditions that may be associated with immunization; (2) coordinates, further develops, maintains and directs activities of the Vaccine Safety Datalink (VSD), a collaborative effort with integrated healthcare organizations, to conduct surveillance and investigate possible AEFI to assess causality and determine risk factors; (3) conducts epidemiologic research on causality of AEFI using the VSD and other data sources, and provides national estimates of incidence of AEFI and background rates of health conditions; (4) leads the nation in developing biostatistical methods for research of AEFI using large linked databases and other data sources, and shares methods for use by other Agencies and public and private entities; (5) conducts clinical research to identify causes of adverse events after immunization, specific populations susceptible to specific adverse events, and prevention strategies through the Clinical Immunization Safety Assessment network, a national network of medical research centers, and other efforts; (6) applies findings from epidemiologic and clinical studies to develop strategies for prevention of AEFI; (7) provides global consultation and leadership for the development, use, and interpretation of vaccine safety surveillance systems, and for the development of shared definitions of specific health outcomes through participation in the Brighton Collaboration and other international organizations; (8) provides data for action to HHS, the Advisory Committee on Immunization Practices, the FDA's Vaccine and Related Biological Products Advisory Committee, Health Resources and Services Administration's Advisory Commission on Childhood Vaccines, and collaborators around the globe including the WHO Global Advisory Committee on Vaccine Safety; and (9) provides timely, accurate communication and education to partners and the public on vaccine safety concerns. Epidemiology Research and Innovations Branch (CVLDG). (1) Identifies and evaluates the efficacy of interventions to prevent HAI and related adverse events or medical errors across the spectrum of healthcare delivery sites including acute and long-term inpatient care, dialysis, and ambulatory settings; (2) identifies gaps in HAI-related knowledge, and conducts prevention research through the Prevention Epicenters cooperative agreements program and Safety and Healthcare Epidemiology Prevention Research Development research contracts; (3) conducts and supports research and evaluates impact of public health practices to prevent HAI, antimicrobial resistance, and related adverse events; (4) improves methods and enables wider use of clinical performance measurements by healthcare facilities and public health entities for specific interventions and prevention strategies designed to safeguard patients and healthcare workers from risk exposures and adverse outcomes through collaborations with extramural partners; (5) conducts applied research to identify and develop innovative methods to detect and monitor HAI and antimicrobial resistance; (6) conducts special studies to identify key risk factors for and provides national estimates of targeted, healthcare-associated adverse events, antimicrobial use and resistance patterns, and the extent to which prevention and control safeguards are in use to protect at-risk patients across the spectrum of healthcare delivery sites; (7) develops new ways to assess the impact of HAI prevention programs; (8) conducts analysis of the return on investment and costs related to prevention efforts and impact of HAI prevention programs; and (9) works with the Emerging Infections Program (EIP) and other partners to identify emerging issues. Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2016-23213 Filed 9-26-16; 8:45 am] BILLING CODE 4160-18-P
![66282 Federal Register / Vol. 81, No. 187 / Tuesday, September 27, 2016 / Notices
coordination with overall OSSAM goals monitoring healthcare worker research to evaluate the safety of
and objectives. vaccination and selected health available and new vaccines; (16) trains
measures in healthcare facilities; (4) EIS Officers and other trainees; (17)
Sherri Berger,
assesses local, regional, national scope coordinates antimicrobial resistance
Chief Operating Officer, Centers for Disease
and burden of infections caused by activities at CDC; (18) works in a
Control and Prevention.
resistant-bacteria in the U.S. through national leadership capacity with public
[FR Doc. 2016–23252 Filed 9–26–16; 8:45 am]
surveillance and special studies, review and private organizations to enhance
BILLING CODE 4160–18–P
of national healthcare data sets, and antimicrobial resistance prevention and
laboratory surveillance programs; (5) control, surveillance and response, and
DEPARTMENT OF HEALTH AND conducts epidemiologic, and basic and applied research; (19) coordinates
HUMAN SERVICES applied laboratory research to identify blood, organ, and other tissue safety at
new strategies to monitor and prevent CDC; and (20) provides expertise and
Centers for Disease Control and infections/antimicrobial resistance, and assistance to HHS, other Federal
Prevention related adverse events or medical errors, agencies, and global partners on efforts
especially those associated with medical and activities related to safe healthcare.
Statement of Organization, Functions, or surgical procedures, indwelling Office of the Director (CVLD1). (1)
and Delegations of Authority medical devices, contaminated Manages, directs, and coordinates the
Part C (Centers for Disease Control products, dialysis, healthcare activities of DHQP; (2) provides
and Prevention) of the Statement of environment, and water; (6) collaborates leadership and guidance on policy
Organization, Functions, and with academic and public health impacting patient and healthcare safety;
Delegations of Authority of the partners to design, develop, and (3) leads targeted patient safety
Department of Health and Human evaluate new approaches to monitoring communication campaigns coordinated
Services (45 FR 67772–76, dated infections and the efficacy of with release of CDC surveillance data,
October 14, 1980, and corrected at 45 FR interventions for preventing infections, infection control guidelines, research
69296, October 20, 1980, as amended improving antibiotic use, and reducing publications, and prevention tools; (4)
most recently at 81 FR 54091–54094, antimicrobial resistance, and related fosters strategic partnerships with
dated August 15, 2016) is amended to adverse events or medical errors; (7) clinical professional organizations to
reflect the reorganization of the Division develops and disseminates evidence- advance implementation of CDC’s
of Healthcare Quality and Promotion, based guidelines and recommendations recommendations and best clinical
National Center for Emerging and to prevent and control HAI, practices; (5) leads communication/
Zoonotic Infectious Diseases, Office of antimicrobial resistance (AR), and media outreach to include social media
Infectious Diseases, Centers for Disease related adverse events or medical errors; platforms and CDC’s patient and
Control and Prevention. (8) collaborates with Federal, state, and healthcare safety Web sites; (6) works
Section C–B, Organization and local public health and private partners with Federal agencies, international
Functions, is hereby amended as to promote nationwide implementation organizations, and other partners on
follows: of CDC guidelines and other evidence- activities related to safe healthcare; (7)
Delete and replace the title and the based interventions to prevent HAI, coordinates state and local activities to
mission and function statements for the antimicrobial resistance, and related monitor and prevent HAI and
Division of Healthcare Quality and adverse events or medical errors among antimicrobial resistance; (8) coordinates
Promotion (CVLD) and insert the patients and healthcare personnel; (9) activities related to infection control in
following: evaluates the impact of evidence-based healthcare and related settings
Division of Healthcare Quality recommendations and interventions including, guideline development and
Promotion (CVLD). Protects patients and across the spectrum of healthcare maintenance, interim guidance
healthcare personnel, and promotes delivery sites; (10) serves as the development, training, consultation,
safety, quality, and value in both Designated Federal Official for the and international activities across
national and international healthcare Healthcare Infection Control Practices DHQP, CDC, and with national and
delivery systems. In carrying out its Advisory Committee (HICPAC); (11) international partners; (9) coordinates
mission, Division of Healthcare Quality serves as the National Reference DHQP activities and collaborates with
Promotion (DHQP): (1) Measures, Laboratory for the identification and the CDC EOC for emergency response to
validates, interprets, and responds to antimicrobial susceptibility testing of emerging infections in healthcare; (10)
data relevant to healthcare-associated staphylococci, anaerobic bacteria, non- coordinates DHQP activities and
infections (HAI); antimicrobial use and tuberculous mycobacterial, and those collaborates with other CIOs and
resistant infections, sepsis, adverse drug gram-negative bacilli causing Federal agencies to prepare healthcare
events, blood, organ and tissue safety, healthcare-associated infections; (12) to respond to emerging threats; (11)
immunization safety, and other related serves as the technical reference oversees the quality of DHQP research
adverse events or medical errors in laboratory for detection and activities and identifies research gaps;
healthcare affecting patients and characterization of other pathogens (12) leads CDC’s activities on blood,
healthcare personnel; (2) investigates related to healthcare, and for organ, and other tissue safety; (13)
and responds to emerging infections, characterizing the contribution of the represents CDC on the Advisory
antimicrobial resistance, and related healthcare environment to HAI and Committee on Blood Safety and
asabaliauskas on DSK3SPTVN1PROD with NOTICES
adverse events among patients and antimicrobial resistant infections; (13) Availability, and the Advisory
healthcare personnel; (3) develops and serves as a global resource for HAI, Committee on Organ Transplantation;
maintains the National Healthcare antimicrobial resistance, and device- (14) works with other Federal agencies,
Safety Network (NHSN), a tool for associated HAI; (14) coordinates state governments, and other public and
monitoring healthcare-associated guidance and research related to private organizations to enhance blood,
infections, antimicrobial use and infection control across CDC and with organ, and other tissue safety through
resistance, measuring healthcare national and international partners; (15) coordination of investigation,
outcomes and processes, and monitors vaccine safety and conducts prevention, response, surveillance,
VerDate Sep<11>2014 17:08 Sep 26, 2016 Jkt 238001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\27SEN1.SGM 27SEN1](https://thefederalregister.org/doc/81_FR_66469/page/1.svg)
![66284 Federal Register / Vol. 81, No. 187 / Tuesday, September 27, 2016 / Notices
related adverse events, contaminated surveillance data into evidence-based partners and the public on vaccine
medical products and devices, and policies and targeted, innovative and safety concerns.
adverse drug events; (7) communicates collaborative interventions. Epidemiology Research and
the results of response activities with Innovations Branch (CVLDG). (1)
Immunization Safety Office (CVLDE).
Federal and state agencies, healthcare Identifies and evaluates the efficacy of
Assesses the safety of new and currently
providers, and the public, with interventions to prevent HAI and related
available vaccines received by children,
recommendations to prevent similar adverse events or medical errors across
adolescents and adults using a variety of the spectrum of healthcare delivery sites
adverse events in the future; and (8) strategies: (1) Conducts ongoing
provides leadership and expert including acute and long-term inpatient
surveillance for the timely detection of care, dialysis, and ambulatory settings;
consultation, guidance, and technical
possible adverse events following (2) identifies gaps in HAI-related
support to and collaborates with other
immunization (AEFI) in collaboration knowledge, and conducts prevention
CDC CIOs and divisions, other HHS
with the Food and Drug Administration research through the Prevention
Operating Divisions, and extramural
(FDA), through coordination and Epicenters cooperative agreements
domestic partners, on the epidemiology,
prevention, and control of HAI, AR, and management of the Vaccine Adverse program and Safety and Healthcare
related adverse events; (9) implements Event Reporting System, the national Epidemiology Prevention Research
state activities to prevent HAI and AR reporting system that acts as an early- Development research contracts; (3)
across healthcare; and (10) leads CDC warning system to detect health conducts and supports research and
activities to promote antimicrobial conditions that may be associated with evaluates impact of public health
stewardship in all healthcare settings. immunization; (2) coordinates, further practices to prevent HAI, antimicrobial
develops, maintains and directs resistance, and related adverse events;
Surveillance Branch (CVLDD). (1)
activities of the Vaccine Safety Datalink (4) improves methods and enables wider
Monitors and evaluates on the national
(VSD), a collaborative effort with use of clinical performance
level the extent, distribution, and
integrated healthcare organizations, to measurements by healthcare facilities
impact of HAI, antimicrobial use and
conduct surveillance and investigate and public health entities for specific
resistance, adverse drug events,
possible AEFI to assess causality and interventions and prevention strategies
healthcare worker safety events, and designed to safeguard patients and
adherence to clinical processes and determine risk factors; (3) conducts
epidemiologic research on causality of healthcare workers from risk exposures
intervention programs designed to and adverse outcomes through
prevent or control adverse exposures or AEFI using the VSD and other data
sources, and provides national estimates collaborations with extramural partners;
outcomes in healthcare; (2) provides (5) conducts applied research to identify
services, including leadership, of incidence of AEFI and background
rates of health conditions; (4) leads the and develop innovative methods to
consultation, and analysis support, for detect and monitor HAI and
statistical methods and analysis to nation in developing biostatistical
methods for research of AEFI using large antimicrobial resistance; (6) conducts
investigators in the branch, division, special studies to identify key risk
and other organizations responsible for linked databases and other data sources,
and shares methods for use by other factors for and provides national
surveillance, research studies, and estimates of targeted, healthcare-
prevention and control of HAI and other Agencies and public and private
entities; (5) conducts clinical research to associated adverse events, antimicrobial
healthcare-associated adverse events; (3) use and resistance patterns, and the
works with the Centers for Medicare identify causes of adverse events after
immunization, specific populations extent to which prevention and control
and Medicaid Services and other safeguards are in use to protect at-risk
partners to develop new metrics and susceptible to specific adverse events,
and prevention strategies through the patients across the spectrum of
support maintenance of National healthcare delivery sites; (7) develops
Quality Forum-approved metrics; (4) Clinical Immunization Safety
Assessment network, a national network new ways to assess the impact of HAI
collaborates with public and private prevention programs; (8) conducts
sector partners to further standardize, of medical research centers, and other
efforts; (6) applies findings from analysis of the return on investment and
integrate, and streamline systems by costs related to prevention efforts and
which healthcare organizations collect, epidemiologic and clinical studies to
develop strategies for prevention of impact of HAI prevention programs; and
manage, analyze, report, and respond to (9) works with the Emerging Infections
data on clinical guideline adherence, AEFI; (7) provides global consultation
and leadership for the development, Program (EIP) and other partners to
HAI, including transmission of multi- identify emerging issues.
drug resistant organisms, and other HAI; use, and interpretation of vaccine safety
(5) coordinates, further develops, surveillance systems, and for the Sherri Berger,
enables wider use, and maintains NHSN development of shared definitions of Chief Operating Officer, Centers for Disease
to obtain scientifically valid clinical specific health outcomes through Control and Prevention.
performance indices that promote participation in the Brighton [FR Doc. 2016–23213 Filed 9–26–16; 8:45 am]
healthcare quality and value at the Collaboration and other international BILLING CODE 4160–18–P
facility, state, and national levels; (6) organizations; (8) provides data for
develops and implements new NHSN action to HHS, the Advisory Committee
modules and provides enrollment and on Immunization Practices, the FDA’s DEPARTMENT OF HEALTH AND
user support for NHSN; (7) improves Vaccine and Related Biological Products HUMAN SERVICES
asabaliauskas on DSK3SPTVN1PROD with NOTICES
surveillance systems by utilizing new Advisory Committee, Health Resources
technology; (8) generates and provides and Services Administration’s Advisory Centers for Disease Control and
NHSN surveillance reports and Commission on Childhood Vaccines, Prevention
analyses, which include collaborative and collaborators around the globe
Statement of Organization, Functions,
analytic projects with partners; and (9) including the WHO Global Advisory
and Delegations of Authority
leads CDC’s national adverse drug Committee on Vaccine Safety; and (9)
events surveillance activities and seeks provides timely, accurate Part C (Centers for Disease Control
to translate population-based communication and education to and Prevention) of the Statement of
VerDate Sep<11>2014 17:08 Sep 26, 2016 Jkt 238001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\27SEN1.SGM 27SEN1](https://thefederalregister.org/doc/81_FR_66469/page/3.svg)
Document Created: 2016-09-27 01:18:52
Document Modified: 2016-09-27 01:18:52
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 81 FR 66282 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR